You are now leaving GSK’s website

This link will take you to a non-GSK website. GSK does not recommend, endorse or accept liability for sites controlled by third-parties.

Continue

Go back

Haleraid is a non-powered device designed to help patients with impaired hand agility (e.g. due to arthritis, muscle weakness) administer aerosol medication from a metered dose inhaler (MDI). It is in the form of a plastic housing within which the MDI is placed, and which facilitates the manual actuation of the MDI, using leverage. Haleraid is a device developed to help patients with impaired hand agility administer GSK’s Seretide (salmeterol xinafoate /fluticasone propionate), Serevent (salmeterol), Flixotide (fluticasone Propionate) and Ventolin (salbutamol) 200 and 120 dose Evohalers. This is a reusable device.

Discontinuation of Haleraid globally

Following a considered review with our manufacturing partner, GSK made a global decision to discontinue Haleraid 200 dose and Haleraid 120 dose. It is now discontinued in all countries.

This is a reusable device and patients can continue to use the Haleraid devices that they have as normal. For any alternatives, patients should discuss these with their healthcare provider.

[Haleraid] is a registered trademark of the GlaxoSmithKline group of companies

Adverse events should be reported. Reporting forms and information can be found at https://yellowcard.mhra.gov.uk/.
Adverse events should also be reported to GlaxoSmithKline UK on 0800 221 441.